title: Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission.
abstract: Rapid growth in the development of new tools and advances in molecular immunology has led to a class of drugs called biologics. While effective, these therapies are costly, typically require continuous administration and often have serious side effects. This review focuses on current therapies and the need for a new class of therapies. A novel class of drugs able to induce and maintain tolerance will be paralleled with the notion that combination therapy appropriately tailored to patient subpopulations may hold the promise of less costly and more effective therapy.
authors.affiliation: Institute of Infectious Diseases and Immunology, Utrecht University, Yalelaan 1, 3584CL Utrecht, The Netherlands.
authors.forename: Willem
authors.initials: W
authors.lastname: van Eden
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lisse
authors.forename: Berent
authors.initials: B
authors.lastname: Prakken
authors.forename: Salvatore
authors.initials: S
authors.lastname: Albani
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001688:Biological Products / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D016503:Drug Delivery Systems / Q000379:methods; D055808:Drug Discovery / Q000379:methods*; D000939:Epitopes / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018448:Models, Immunological; D012074:Remission Induction; D013601:T-Lymphocytes / Q000187:drug effects; D057170:Translational Research, Biomedical / Q000379:methods
chemical_list: D001688:Biological Products; D000939:Epitopes; D007155:Immunologic Factors